New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
07:02 EDTSLXPSalix announces outcome for TARGET 3 study evaluating rifaximin
Salix Pharmaceuticals announced the "successful" outcome of TARGET 3, a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeat treatment with rifaximin 550 mg TID for 14 days in subjects with irritable bowel syndrome with diarrhea, or IBS-D, who respond to an initial treatment course with rifaximin 550 mg TID for 14 days. In the study a statistically significant greater proportion of rifaximin treated subjects responded to repeat treatment as assessed by the composite primary endpoint of IBS-related abdominal pain and stool consistency during the 4 week treatment-free follow-up period in the Double Blind Repeat Treatment Phase. The company said, "The outcome of TARGET 3 serves to corroborate the results of TARGET 1 and TARGET 2, the confirmatory Phase 3 trials for our supplemental New Drug Application seeking marketing approval for rifaximin as a treatment option for irritable bowel syndrome with diarrhea.”
News For SLXP From The Last 14 Days
Check below for free stories on SLXP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
07:21 EDTSLXPSalix submits response to FDA's CRL regarding XIFAXAN 550 mg tablets sNDA
Salix Pharmaceuticals announced that on August 29, it submitted its response to the March 7, 2011, FDA Complete Response Letter, or CRL, regarding the Company’s supplemental New Drug Application, or sNDA, for XIFAXAN 550 mg tablets for the proposed indication of the treatment of irritable bowel syndrome with diarrhea or IBS-D. Upon receipt of Salix’s response, the FDA will have six months to issue a response.
August 20, 2014
17:59 EDTSLXPAllergan talks with Salix in defense tactic said to be dormant, Bloomberg says
Subscribe for More Information
17:35 EDTSLXPAllergan said to explore options outside of Salix acquisition, Bloomberg says
Subscribe for More Information
10:53 EDTSLXPAnalysts say Salix takeover would boost Allergan
Subscribe for More Information
09:46 EDTSLXPAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
07:19 EDTSLXPPossible Allergan Salix deal could be 8% accretive in '15-'16, says Wells Fargo
After The Wall Street Journal reported that Allergan (AGN) had approached Salix (SLXP) and other companies about a potential acquisition, Wells Fargo thinks that a largely debt financed purchase of Salix could be 8% accretive for Allergan in 2015-2016, reaching 12% accretion in 2018.
07:04 EDTSLXPSalix buyout price could be near $192 per share, says William Blair
William Blair believes a combined Allergan (AGN) and Salix (SLXP) would be very attractive. The firm estimates a potential takeover price for Salix towards the high end of its $176-$192 per share range. Salix rose 16% yesterday to $160.80 after Wall Street Journal reported that Allergan approached the company and at least one other about a takeover.
August 19, 2014
17:14 EDTSLXPOn The Fly: Closing Wrap
Subscribe for More Information
16:52 EDTSLXPAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
Subscribe for More Information
14:40 EDTSLXPSterne Agee says Allergan could pay up to $190 for Salix and still be accretive
Subscribe for More Information
13:28 EDTSLXPJazz moves higher after WSJ report of Salix approach by Allergan
Subscribe for More Information
13:15 EDTSLXPSalix options active after WSJ report of Allergan approach
Subscribe for More Information
13:13 EDTSLXPAllergan approached Salix, one other about takeover, WSJ reports
Subscribe for More Information
13:06 EDTSLXPSalix jumps 6% to $147.85 after WSJ report of Allergan approach
Subscribe for More Information
13:05 EDTSLXPAllergan approached Salix about takeover, WSJ reports
07:02 EDTSLXPSalix announces early termination of HSR Waiting Period for Cosmo transaction
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use